Afexa Life Sciences Inc.

Afexa Life Sciences Inc.

October 07, 2010 19:07 ET

Afexa to Present at the Canaccord Genuity Healthy Living Conference, Wednesday, October 13 at 2:15 PM EDT

EDMONTON, ALBERTA--(Marketwire - Oct. 7, 2010) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA), makers of Canada's #1 selling cold and flu remedy COLD-FX®, today announced that its Chairman and CEO, Jack Moffatt, will present a Company overview highlighting Afexa's product pipeline and growth opportunities at the Canaccord Genuity Third Annual Healthy Living® Conference. The presentation will take place on Wednesday, October 13 at 2:15 PM EDT at the Intercontinental Hotel in Boston. The conference will showcase 24 public and private companies representing potential investment opportunities in health and wellness.

The Afexa presentation will be web cast live and archived for later replay. To access the web cast, please visit


Afexa Life Sciences Inc., founded in 1992, strives to deliver the most trusted health brand on the planet through pioneering evidence-based natural medicines that empower people to achieve their health potential. The Company's patented ChemBioPrint discovery and standardization technology enables the development of effective and safe medicines from complex natural sources, while ensuring reliable health benefits and batch-to-batch consistency. COLD-FX, a ChemBioPrint product, is the Company's flagship product and Canada's leading over-the-counter (OTC) cold and flu remedy. It is officially indicated in Canada to help reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system. COLD-FX products have natural product licenses (NPNs) and are supported by scientific evidence, including randomized, double-blind, placebo-controlled clinical trials.

Contact Information